Posenacaftor is an investigational small molecule belonging to the CFTR modulator class, developed to treat cystic fibrosis by correcting defective chloride channel function associated with specific F508del… Read more
Posenacaftor is an investigational small molecule belonging to the CFTR modulator class, developed to treat cystic fibrosis by correcting defective chloride channel function associated with specific F508del mutations. This category includes high-quality reference standards for Posenacaftor API, alongside its identified impurities and metabolites necessary for rigorous analytical method development and quality control validation. Pharmaceutical laboratories rely on these standards for accurate impurity profiling and to ensure the precision of analytical testing procedures. Additionally, stable isotope-labelled versions of the compound are available to serve as internal standards, facilitating accurate quantification in complex bioanalytical assays during clinical research and pharmacokinetic studies. By providing access to these essential materials, analytical chemists can effectively support the development and regulatory assessment of therapies targeting cystic fibrosis.